More on SRPT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $17.57 |
|
|||
| Open | $17.75 | ||||
| 52 Wk High | $63.73 | ||||
| 52 Wk Low | $8.00 | ||||
| Day High | $17.76 | ||||
| Day Low | $17.21 | ||||
| P/E | N/A | ||||
| EPS | $-5.69 | ||||
| Volume | 2,609,957 | ||||
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics (SRPT) PT Lowered to $20 at JPMorgan
- Sarepta's Elevidys shows benefit in older Duchenne patients
- Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Olde
- Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
- Jefferies on Sarepta Therapeutics (SRPT): 'The risk/reward seems favorable'
- Sarepta to present Phase 4 Duchenne drug data at neuromuscular meeting
- Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
- Form 8-K Sarepta Therapeutics, For: Sep 23
- Selloff in this biotech stock is overdone – Mizuho
Entities mentioned with SRPT
- FDA | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
